TY  - JOUR
AU  - Hao, Shuai
AU  - Luo, Chonglin
AU  - Abukiwan, Alia
AU  - Wang, Guangxia
AU  - He, Jinjun
AU  - Huang, Lingyun
AU  - Weber, Claudia E M
AU  - Lv, Na
AU  - Xiao, Xueyuan
AU  - Eichmüller, Stefan B
AU  - He, Dacheng
TI  - miR-137 inhibits proliferation of melanoma cells by targeting PAK2.
JO  - Experimental dermatology
VL  - 24
IS  - 12
SN  - 0906-6705
CY  - Oxford
PB  - Wiley-Blackwell
M1  - DKFZ-2017-02693
SP  - 947 - 952
PY  - 2015
AB  - MicroRNAs (miRNA) are key players in a variety of cancers including malignant melanoma. miR-137 has been reported to be a tumor suppressor in melanoma and several targets have been identified for this miRNA. We previously developed a novel proteomics technology, (35) S in vivo/vitro labelling analysis for dynamic proteomics (SiLAD). Because of its high sensitivity in analysing protein expression rates, SiLAD has the potential to unravel miRNA effects on mRNAs coding for proteins with long half-lives or high abundance. Using SiLAD, we discovered that miR-137 significantly downregulated the expression rate of p21-activated kinase 2 (PAK2) in melanoma cells. Bioinformatics analysis predicted PAK2 as a direct target of miR-137, which was confirmed by luciferase reporter assay and Western blot analysis. We found that overexpression of miR-137 inhibited the proliferation of melanoma cells, which could be phenocopied by knockdown of PAK2 using siRNAs. Furthermore, overexpression of PAK2 restored miR-137-mediated suppression of cell proliferation. These findings indicate that miR-137 could inhibit proliferation through targeting PAK2 in melanoma cells.
KW  - MIRN137 microRNA, human (NLM Chemicals)
KW  - MicroRNAs (NLM Chemicals)
KW  - RNA, Neoplasm (NLM Chemicals)
KW  - RNA, Small Interfering (NLM Chemicals)
KW  - PAK2 protein, human (NLM Chemicals)
KW  - p21-Activated Kinases (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:26186482
DO  - DOI:10.1111/exd.12812
UR  - https://inrepo02.dkfz.de/record/126665
ER  -